logo

KYMR

Kymera Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.95 / 10
Netural

Financial analysis yields an inadequate rating (4.0/10). Strengths include high Revenue-MV, Profit-MV, Cash-MV, and Gross profit margin, but weaknesses are evident in Fixed assets turnover ratio and Net profit / Total profit percentage. The PB-ROE factor is particularly concerning at 2.2870, placing it in Group 3 with a 0/3 quality score. Overall, the fundamental structure is unfavorable, warranting caution and further scrutiny of upcoming earnings for any positive surprises.

Fundamental(3.95)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-5.04
Score2/3
Weight19.16%
1M Return11.69%
Inventory turnover ratio
Value47.85
Score3/3
Weight7.38%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight16.87%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight12.57%
1M Return7.79%
PB-ROE
Value2.29
Score0/3
Weight5.74%
1M Return3.56%
Current assets turnover ratio
Value0.07
Score1/3
Weight-0.63%
1M Return-0.48%
Fixed assets turnover ratio
Value0.76
Score1/3
Weight-1.99%
1M Return-1.64%
Asset-MV
Value-0.50
Score2/3
Weight28.68%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight12.59%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.37%
1M Return-0.30%
Is KYMR fundamentally strong?
  • KYMR scores 3.95/10 on fundamentals and holds a Fair valuation at present. Backed by its -25.18% ROE, -674.80% net margin, -22.81 P/E ratio, 6.64 P/B ratio, and -53.85% earnings growth, these metrics solidify its Netural investment rating.